Treating Cancer With Precision
News
Categories
Sign up
Featured Posts
Archive
Follow Us
- Jan 20
New Alpha DaRT Research Collaboration on Immune Stimulation in the Treatment of Breast Cancer
JERUSALEM, Jan 20, 2022 – Alpha Tau Medical Ltd. (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha...
- Jan 10
Results of First US Clinical Trial of Alpha DaRT™
Alpha Tau Announces Results of First US Clinical Trial of Alpha DaRT™ in Malignant Skin & Soft Tissue Cancers, Showing Complete Response...
- Jan 3
Completion of Enrollment of Japanese Pivotal Clinical Trial in Recurrent Head & Neck Cancer
JERUSALEM, Dec. 31, 2021 -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha...
- Nov 4, 2021
Enrollment of First Patient in Combination Trial of Alpha DaRT™ and Pembrolizumab (Keytruda®)
JERUSALEM, Nov. 3, 2021 -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha...
- Oct 26, 2021
Completion of Enrollment in 1st US Clinical Trial & Achievement of 1st Primary Objective
JERUSALEM, Oct. 25, 2021 -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha...
- Oct 12, 2021
Alpha Tau Receives FDA's Breakthrough Device Designation for the Treatment of Recurrent GBM
JERUSALEM, Oct. 8, 2021 -- Alpha Tau Medical, the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, is pleased to...
- Jul 11, 2021
Alpha Tau & Healthcare Capital Corp. to Combine and Create A $1-Billion Publicly Traded Company
Alpha Tau and Healthcare Capital Corp. to Combine and Create A Publicly Traded Company Focused on Transforming the Treatment of Solid...
- Jul 8, 2021
First Alpha DaRT Patient Treated in the US as Part of Pilot Multicenter Skin Cancer Trial
Jerusalem, Israel, July 6, 2021 - Alpha Tau Medical, the developer of the pioneering alpha-radiation cancer therapy Alpha DaRTTM,...
- Jun 13, 2021
Alpha Tau Receives Breakthrough Device Designation from the FDA for Alpha DaRT™
JERUSALEM, June 8, 2021 /PRNewswire/ -- Alpha Tau Medical, the developer of the pioneering alpha-radiation cancer therapy Alpha DaRT,TM...
- Jun 4, 2020
Alpha Tau Medical Announces Successful Completion of New $26 Million Funding Round
Tel Aviv, Israel, June 4, 2020 - Alpha Tau Medical, the developer of breakthrough alpha-radiation cancer therapy Alpha DaRT, is pleased...